✦ LIBER ✦

Pharmacokinetics of SPI-1620 in a Phase I, open label, ascending dose study of the safety, tolerability, pharmacokinetics and pharmacodynamics of the endothelin B receptor agonist, SPI-1620, in recurrent or progressive carcinoma

✍ Scribed by Reddy, Guru; Tolcher, Anthony; Gulati, Anil; Chawla, Shanta; Allen, Lee F.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

OR7-8: A phase II randomised, open-label

✍ Trainer, P.J.; Newell-Price, J.; Ayuk, J.; Aylwin, S.; Drake, W.M.; Rees, A.; Ch 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 449 KB

A Double-Blind, Randomized Placebo-Contr

✍ Hellström, Per M. ;Tack, Jan F. ;Stephens, Kimberley E. ;Barton, Matthew E. ;Vas 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 102 KB

411 POSTER A phase I, open-label, dose-e

✍ R. Salgia; A. Peterson; S. Eppler; W. Yu; B. Polite; D. Geary; E. Wesolowski; M. 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 61 KB